| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/13/2006 | WO2006073197A1 1-thio-d-glucitol derivatives |
| 07/13/2006 | WO2006073190A1 Composition for external use |
| 07/13/2006 | WO2006073181A1 Cell activator, cell death inhibitor and cell death promoter |
| 07/13/2006 | WO2006073172A1 12-oxy-13-amino-containing 16-membered cyclic macrolide derivative and process for producing the same |
| 07/13/2006 | WO2006073167A1 Pyrrolidine derivatives |
| 07/13/2006 | WO2006073162A1 Method for improving storage stability of nadh or nadph or salt thereof |
| 07/13/2006 | WO2006073154A1 Medicinal composition and process for producing the same |
| 07/13/2006 | WO2006073151A1 Novel fermentation product |
| 07/13/2006 | WO2006073147A1 Remedial agent for fat toxicity |
| 07/13/2006 | WO2006073126A1 Preventive and remedy for dry eye associated with chronic graft versus host disease |
| 07/13/2006 | WO2006073042A1 ACTIVATOR FOR Nrf2-DEPENDENT GENE |
| 07/13/2006 | WO2006072966A1 High-bulk density carisoprodol suitable for direct compression |
| 07/13/2006 | WO2006072957A1 Anti-arrythmic drugs and cholesterol absorption inhibitors as neuroprotective agents for the treatment of neurodegenerative and autoimmune disorders |
| 07/13/2006 | WO2006072881A1 Methods and compositions for treating diabetes, metabolic syndrome and other conditions |
| 07/13/2006 | WO2006072878A1 Oral dosage forms of sertraline having controlled particle size and processes for their preparation |
| 07/13/2006 | WO2006072833A1 Imidazole derivatives as enzyme reverse transcriptase modulators |
| 07/13/2006 | WO2006072832A1 Fast-disintegrating dosage forms of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene |
| 07/13/2006 | WO2006072831A1 Pyrrolopyrazoles, potent kinase inhibitors |
| 07/13/2006 | WO2006072809A2 Formulations that optimize intracellular concentration of nicotinamide adenine (nad+) and methods of use to protect cells and treat diseases and conditions |
| 07/13/2006 | WO2006072792A2 Compounds which bind to the active site of protein kinase enzymes |
| 07/13/2006 | WO2006072783A1 Sulfasalazine analogues as nf-kb inhibitors |
| 07/13/2006 | WO2006072736A1 N- (heteroaryl) -1h-indole-2-carb0xamide derivatives and their use as vanilloid trpv1 receptor ligands |
| 07/13/2006 | WO2006072732A1 Use of cyproterone acetate for treating aggressive behaviours in patients suffering from dementia |
| 07/13/2006 | WO2006072647A1 The use of a lignan for the manufacture of a composition for preventing or alleviating of symptoms relating to estrogen deficiency |
| 07/13/2006 | WO2006072600A1 Androstane 17-alpha-carbonate for use in the treatment of inflammatory and allergic conditions |
| 07/13/2006 | WO2006072599A2 Androstane 17-alpha carbonate derivatives for use in the treatment of allergic and inflammatory conditions |
| 07/13/2006 | WO2006072588A1 Substituted 2-amino-quinazolin-4-cn compounds for use in the treatment of cns disorders, pain, stroke, addiction and epilepsy, their preaparation and use as intermediates |
| 07/13/2006 | WO2006072577A1 Process for preparing granulates comprising amoxicillin |
| 07/13/2006 | WO2006072562A1 Treatment of hcv disorders |
| 07/13/2006 | WO2006072467A1 18-methyl-19-nor-17-pregn-4-en-21,17-carbolactones and pharmaceutical preparations comprising the same |
| 07/13/2006 | WO2006072448A1 Substituted benzimidazoles for treatment of histomoniasis |
| 07/13/2006 | WO2006072440A1 Plastic bottle for oxaliplatin solution |
| 07/13/2006 | WO2006072436A1 [4-(heteroaryl) piperazin-1-yl]-(2,5-substituted -phenyl)methanone derivatives as glycine transporter 1 (glyt-1) inhibitors for the treatment of neurological and neuropsychiatric disorders |
| 07/13/2006 | WO2006072435A1 Sulfanyl substituted phenyl methanones as glycine transporter 1 (glyt-1) inhibitors for the treatment of neurological and neuropsychiatric disorders |
| 07/13/2006 | WO2006072432A1 Benzoyl-tetrahydropyridine as glyt-1 inhibitors |
| 07/13/2006 | WO2006072430A1 Phenyl diazepane carboxamides and annelated phenyl piperazine carboxamides containing oxygen and used as dopamine d3 antagonists |
| 07/13/2006 | WO2006072424A1 PHARMACEUTICAL COMPOSITION FOR CONTROLLED RELEASE OF β-LACTAM ANTIBIOTICS IN COMBINATION WITH β-LACTAMASE INHIBITORS |
| 07/13/2006 | WO2006072415A1 Use of selected cgrp antagonists for controlling menopausal hot flashes |
| 07/13/2006 | WO2006072413A1 Use of selected cgrp antagonists in combination with other antimigraine medical substances for the treatment of migraine |
| 07/13/2006 | WO2006072370A1 Selected benzofuran derivatives |
| 07/13/2006 | WO2006072367A1 Solid, orally applicable pharmaceutical administration forms containing rivaroxaban having modified release |
| 07/13/2006 | WO2006072362A1 (5s) -3-[(s)-fluoro (4-trifluoromethylphenyl) methyl]-5,6,7,8-tetrahydroquinoline-5-ol derivatives and use thereof as cetp inhibitors |
| 07/13/2006 | WO2006072354A1 Squaric acid derivatives |
| 07/13/2006 | WO2006072353A1 Azetidine-substituted pyrazolines as par-1 antagonists |
| 07/13/2006 | WO2006072351A1 Heteroaryl-substituited pyrazolines as par-1 antagonists |
| 07/13/2006 | WO2006072350A1 Cyanoguanidine-substituted pyrazolines |
| 07/13/2006 | WO2006072349A1 Thiophene-substituited pyrazolines |
| 07/13/2006 | WO2006072347A2 Alkinyl-substituted thiophenes |
| 07/13/2006 | WO2006072259A2 Taurine synthesis, production and utility as a medicine |
| 07/13/2006 | WO2006072213A1 Anti-depression formulations |
| 07/13/2006 | WO2006072203A1 Inhibitor or promoter of uridinediphosphate glucuronosyltransferase2b (ugt2b) |
| 07/13/2006 | WO2006072201A1 Particle adjuvant for hifu therapy and the use thereof |
| 07/13/2006 | WO2006072200A1 Adjuvant of fluorocarbon emulsions for hifu therapy and the use thereof |
| 07/13/2006 | WO2006072189A2 Spiro [bornyl - 2 , 4' - ( 1 , 3 -dioxanes) ] and their uses as fragrance ingredients |
| 07/13/2006 | WO2006072172A1 Compounds and methods for regulating triglyceride levels |
| 07/13/2006 | WO2006072171A1 Method for blood glucose control in a mammal by n-acylated glucosamines |
| 07/13/2006 | WO2006057915A3 2-methylene-19,21-dinor-1alpha-hydroxy-bishomopregnacalciferol |
| 07/13/2006 | WO2006057902A3 2alpha-methyl-19-nor-1alpha-hydroxy-homopregnacalciferol and its uses |
| 07/13/2006 | WO2006057901A3 2-METHYLENE-19-NOR-1α-HYDROXY-17-ENE-HOMOPREGNACALCIFEROL AND ITS USES |
| 07/13/2006 | WO2006057011A3 Use of chitosan for stimulating bone healing and bone formation |
| 07/13/2006 | WO2006051549A3 Combination therapy associating preferably a ceramide with a cytotoxic drug |
| 07/13/2006 | WO2006050949A3 Superagonistic anti-cd28 antibody |
| 07/13/2006 | WO2006050471A3 Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use |
| 07/13/2006 | WO2006049933A3 Compositions and methods for the treatment of obesity and sexual dysfunction |
| 07/13/2006 | WO2006047522A8 Hypoestoxides, derivatives, agonists and crude extracts thereof for use in topical compositions |
| 07/13/2006 | WO2006047475A3 Detection and analysis of ophthalmically-relevant fluorescent molecules |
| 07/13/2006 | WO2006047362A3 Transdermal delivery systems |
| 07/13/2006 | WO2006047322A3 A method for treatment and prevention of bacterial vaginosis |
| 07/13/2006 | WO2006043149A3 Novel dicarboxylic acid derivatives |
| 07/13/2006 | WO2006042478A8 Small-molecule inhibitors of coronaviral main protease, their preparation and use |
| 07/13/2006 | WO2006042441A3 Novel agents for preventing and treating disorders connected to impaired neurotransmission |
| 07/13/2006 | WO2006041900A3 SUBSTITUTED N-ARYL-1H-PYRAZOLO[3,4-b]QUINOLIN-4-AMINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS |
| 07/13/2006 | WO2006040598A3 Process for the preparation of suspension aerosol formulations, wherein the particles are formed by precipitation inside an aerosol canister |
| 07/13/2006 | WO2006038116A3 Triazolopyridine derivatives as antibacterial agents |
| 07/13/2006 | WO2006037028A3 Methods and compositions for treating flaviviruses, pestiviruses and hepacivirus |
| 07/13/2006 | WO2006036732A3 Process for releasing and extracting phosphatides from a phosphatide-containing matrix |
| 07/13/2006 | WO2006036681A3 Cartilage filling device |
| 07/13/2006 | WO2006034956A3 Osteogenic oligonucleotides and uses thereof |
| 07/13/2006 | WO2006034093A3 3- (2-acylamino-1-hydroxyethyl)- morpholine derivatives and their use as bace inhibitors |
| 07/13/2006 | WO2006034080A3 Formulation comprising itraconazole |
| 07/13/2006 | WO2006034003A3 Compounds, compositions and methods of inhibiting a-synuclein toxicity |
| 07/13/2006 | WO2006032977A3 Stabilized leukotriene b4 (ltb4) agent pharmaceutical |
| 07/13/2006 | WO2006032879A3 Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (mtc) |
| 07/13/2006 | WO2006031513A3 Aryl spirolactam cgrp receptor antagonists |
| 07/13/2006 | WO2006030977A3 Imidazole derivatives as large conductance calcium-activated k channel openers |
| 07/13/2006 | WO2006029577A8 Methods and compositions for the treatment of hyperlipidemia |
| 07/13/2006 | WO2006027705A3 Synthesis of triethylenetetramines |
| 07/13/2006 | WO2006026555A3 Neuroprotective effect of solubilized udca in focal ischemic model |
| 07/13/2006 | WO2006023707A3 2-aminothiophenecarboxamides useful as cancer chemotherapeutic agents |
| 07/13/2006 | WO2006023515A3 Novel thiazole inhibitors of fructose 1,6-bisphosphatase |
| 07/13/2006 | WO2006021833A3 Bisbenzamidines for the treatment of pneumonia |
| 07/13/2006 | WO2006021457A3 Pyrimidine derivatives |
| 07/13/2006 | WO2006020417A3 Alkene mimics |
| 07/13/2006 | WO2006019886A3 Pyrrolo(oxo)isoquinolines as 5ht ligands |
| 07/13/2006 | WO2006017468A3 Antibacterial agents |
| 07/13/2006 | WO2006016020A3 Nanoparticles comprising a core essentially consisting of a cyanoacrylic polymer and a shell of an amphiphilic polymer and, optionally, an active principle, preferably bisulfan |
| 07/13/2006 | WO2006012563A3 Method for the treatment and diagnosis of certain psychiatric disorders related to the menstrual cycle |
| 07/13/2006 | WO2006008003A3 Diagnostics and therapeutics for diseases associated with vasoactive intestinal peptide receptor 1 (vpac1) |
| 07/13/2006 | WO2006004833A3 Pyrrolotriazine kinase inhibitors |
| 07/13/2006 | WO2006004738A3 Methods to inhibit histone acetyltransferase using glycosaminoglycans |